HSV-1 mobility as a function of exogenously added polyclonal anti-HSV-1 and or non-specific anti-Biotin IgG control. a Sample trace of fast-moving HSV-1 subpopulations, with Deff ≥ 0.347 µm2/s. b Sample trace of trapped virus in CVM. c Ensemble-averaged <Deff> and d percent of fast-moving viruses in CVM treated with 5 µg/mL pAb. Paired two-tailed t-test (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, n = 82).